Infliximab-Dyyb
1 NDC across 1 manufacturer|0 Generic,1 Brand
Infliximab-Dyyb is used to treat psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $40 million on Infliximab-Dyyb across 7,306 claims for 1,482 beneficiaries.
Infliximab-Dyyb is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $491.55 to $491.55 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$491.55 – $491.55
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing INFLIXIMAB-DYYB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
INFLECTRA 100 MG VIAL | $491.5457 per EA | — |
Frequently Asked Questions
What is Infliximab-Dyyb used to treat?
Infliximab-Dyyb is used to treat psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Infliximab-Dyyb?
In 2024, Medicare Part D spent $40 million on Infliximab-Dyyb across 7,306 claims for 1,482 beneficiaries.
How many Infliximab-Dyyb products are on the market?
The Infliximab-Dyyb drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Infliximab-Dyyb?
NADAC reference prices for Infliximab-Dyyb range from $491.5457 to $491.5457 per EA.
Which manufacturers make Infliximab-Dyyb?
1 manufacturer lists Infliximab-Dyyb in NADAC. Ranked by number of NDCs, the largest are Pfizer Inc. (1).